Pasithea Therapeutics Corp. Cash Flow Statement
KTTA|2 years of annual SEC 10-K data (FY2021-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$3M
FY2022
Free Cash Flow
-$3M
FY2022
Capital Expenditures
$21,503
Cash used for long-term assets
Dividends Paid
N/A
FY2022
Pasithea Therapeutics Corp. used $3M in operating cash flow and negative free cash flow of $3M in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 |
|---|---|---|
| Net Income | -$2.2M | -$41.0K |
| Depreciation & Amortization | $1.4K | $1.4K |
| Operating Cash Flow | -$3.2M | -$38.7K |
| Capital Expenditures | $21.5K | $21.5K |
| Free Cash Flow | -$3.2M | -$60.2K |
| FCF Margin | -21216.1% | -399.6% |